MONTREAL, QUEBEC -- (MARKET WIRE) -- 11/13/07 -- ProMetic Life
Sciences Inc. (TSX: PLI) ("ProMetic") announced today that ProMetic's
abstract on its PBI-1402 Phase II clinical trial in patients with
chemotherapy-induced anemia ("CIA") is now available on the American
Society of Hematology's ("ASH") Web site under the heading "Annual
Meeting Abstracts" http://www.hematology.org/meetings/2007/index.cfm.

More substantive information will be reported in conjunction with a
poster to be presented at ASH's annual meeting on December 9, 2007.

About PBI-1402
PBI-1402 is an orally active compound being developed to treat
different types of anemia, such as CIA. ProMetic has recently
expanded its clinical program for PBI-1402 for treatment of patients
with cancer-related anemia, such as myelodysplastic syndrome, a
condition often referred to as "pre-leukemia". Clinical trials in
patients with anemia associated to chronic kidney diseases are also
scheduled to commence shortly.

About chemotherapy-induced anemia ("CIA")
Anemia is one of the most serious side effects caused by
chemotherapy. Anemia is a condition in which red blood cells and
hemoglobin are below normal levels. CIA is associated with a reduced
quality of life and possible compromised treatment outcomes. Of the
estimated 1.3 million new patients that undergo chemotherapy annually
in the U.S., it is believed that approximately two third of these
patients will develop CIA. Certain types of chemotherapy regimens are
associated with more frequent and severe anemia often leading to the
patients requiring blood transfusions. The treatment with rhEPO is
active in only 50-60 percent of CIA patients. Typical doses of rhEPO
required to treat CIA patients are two- to three-fold higher than
those used to treat anemia in dialysis patients.

About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and
marketing of a variety of commercial applications derived from its
proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of
pathogens. ProMetic is also active in therapeutic drug development
with the mission to bring to market effective, innovative, lower
cost, less toxic products for the treatment of hematology and cancer.
Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics.
Headquartered in Montreal (Canada), ProMetic has R&D facilities in
the U.K., the U.S. and Canada, manufacturing facilities in the U.K.
and business development activities in the US, Europe, Asia and in
the Middle-East.